24. A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-
group, Multicenter Study to Evaluate the Efficacy and
Safety of Sotagliflozin compared to Glimepiride or Placebo Added to Metformin in Patients with Type
2 Diabetes who have Inadequate Glycemic Control with
Metformin Monotherapy. Completed 2019 Principal Investigator.
25. A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess Safety,
Tolerability, and Renal Effects of TMX-049 in Subjects with Type 2 Diabetes and Albuminuria.
Completed 2019. Principal Investigator.
26. TRAVERSE Study. Testosterone Replacement Therapy for Assessment of long-term Vascular Events
and Efficacy Response in Hypogonadal Men. Sponsor AbbVie. Aug 2018, ongoing. Principal
Investigator.
27. A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate
the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with
Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP-
4) With or Without Metformin. Completed 2019, Principal Investigator.
28. Phase3B/4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in comparison to a
Tumor Necrosis Factor (TNF) Inhibitor in Subject with Rheumatoid Arthritis. Pfizer. Completed
2019. Principal Investigator.
29. Efficacy and Safety of Sotagliflozin Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who
Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic
Agents (SOTA-INS) Completed 2019. Principal Investigator.
30. LIXILAN-D (DIVERSITY): A 26-week randomized, open-label, active-controlled, 2-treatment arm,
parallel-group multi-center study, comparing the Efficacy and Safety of Soliqua Versus Lantus in
Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal
Insulin and Oral Antidiabetic Agents (LixiLan-D) Dec 2018 completed Principal Investigator.
31. Randomized, Open label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity
of Alternating Use of SAR341402 and NovoLog® versus Continuous Use of NovoLog in Patients with
Type 1 Diabetes Mellitus also Using Insulin Glargine. Mar 2020. Principal Investigator.
32. A phase 3, multicenter, randomized, double-blind, placebo-controlled, active reference
(adalimumab) study evaluating the efficacy and safety of bimekizumab in the treatment of subjects
with active psoriatic arthritis. Jan 2021, Principal Investigator.
33. PROMINENT prominent pemafibrate to reduce cardiovascular outcomes by reducing triglycerides
in patients with diabetes. Ongoing started 2017, Principal Investigator.
34. SAPPHIRE; A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of
Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricaemia, Jan
2022, Principal Investigator.
35. A Randomized, Non-Inferiority, Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy
and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women with Osteoporosis
(Wearable Study) Jan 2022, Principal Investigator
36. AbbVie / “24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving
Testosterone Replacement Therapy” Mar 2022. Principal Investigator.
37. ANJ900D3501: A randomized, multicenter, double-blind, parallel-group, placebo-and comparator-
controlled study to compare the glycemic effects, safety, and tolerability of metformin hydrochloride
delayed-release tablets in patients with type 2 diabetes mellitus with varying renal function from
normal up to CKD3B Sep, 2021 ongoing. Principal Investigator.
38. D9488C00001: A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to
Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression
in Participants with CKD and Hyperkalaemia or at Risk of Hyperkalaemia Oct 2021 ongoing.
39. CSL346_2001: A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of
Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in
Subjects with Diabetic Kidney Disease, Mar 2021, ongoing, Principal Investigator.